Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to MTX

NCT02305849 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT02305849
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02305849 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to MTX
Lead sponsor
Astellas Pharma Inc
Phase
Phase 3
Overall status
Completed
Start date
July 25, 2014
Completion date
November 28, 2017
Enrollment
519 (actual)
Sites
146

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis